Results 31 to 40 of about 17,271 (194)
Inhibition of Wnt/β‐catenin pathway overcomes therapeutic resistance to abiraterone in castration‐resistant prostate cancer [PDF]
Abiraterone acetate has been clinically approved for the treatment of patients with advanced‐stage prostate cancer. It reduces testosterone production by blocking the enzyme cytochrome P450 17 alpha‐hydroxylase.
Shankar, Eswar +12 more
core +1 more source
Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer [PDF]
Considerable evidence from both clinical and experimental studies suggests that androgen receptor variants, particularly androgen receptor variant 7 (AR-V7), are critical in the induction of resistance to enzalutamide and abiraterone.
Zhu, Yezi +4 more
core +1 more source
Mitigating ipatasertib‐induced glucose increase through dose and meal timing modifications
Ipatasertib, an AKT inhibitor, in combination with prednisone and abiraterone, is under evaluation for the treatment of metastatic castration‐resistant prostate cancer (mCRPC). Hyperglycemia is an on‐target effect of ipatasertib.
Dhruvitkumar S. Sutaria +8 more
doaj +1 more source
Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer
Suppression of gonadal testosterone synthesis represents the standard first line therapy for treatment of metastatic prostate cancer. However, in the majority of patients who develop castration-resistant prostate cancer (CRPC), it is possible to detect ...
Mark N Stein +4 more
doaj +1 more source
Abiraterone induces SLCO1B3 expression in prostate cancer via microRNA-579-3p
Understanding mechanisms of resistance to abiraterone, one of the primary drugs approved for the treatment of castration resistant prostate cancer, remains a priority.
Roberto H. Barbier +7 more
doaj +1 more source
Secondary hormone therapy, abiraterone and enzalutamide, has improved outcomes for metastatic castration-resistant prostate cancer (mCRPC) and prolonged patients’ lives significantly.
Yi-Ting Lin +12 more
doaj +1 more source
Background Over the past decade, abiraterone and enzalutamide have largely replaced ketoconazole as oral treatments for castration‐resistant prostate cancer (CRPC).
Megan E. V. Caram +9 more
doaj +1 more source
Background Abiraterone and enzalutamide are castration‐resistant prostate cancer (CRPC) therapies with potentially distinct associations with mental health symptoms given their differing antiandrogen targets.
Phoebe A. Tsao +8 more
doaj +1 more source
The present work deals with the preparation and in vitro evaluation of liposomal formulations of abiraterone acetate. In the present work, abiraterone acetate-loaded liposomal formulation was formulated by thin lipid film method.
Sudipta Das +4 more
doaj +1 more source
SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity. [PDF]
deletions and mutations frequently cooccur in prostate cancer with lower frequencies reported in castration-resistant prostate cancer (CRPC). We monitored CHD1 expression during disease progression and assessed the molecular and clinical characteristics
Christova, Rossitza +65 more
core +1 more source

